Valuation: Orexo AB

Capitalization 585M 54.67M 52.05M 49.09M 43.36M 77.46M 4.74B 85.96M 217M 1.98B 205M 201M 8.31B P/E ratio 2024
-2.97x
P/E ratio 2025 * -9.46x
Enterprise value 951M 88.98M 84.71M 79.9M 70.57M 126M 7.71B 140M 352M 3.22B 334M 327M 13.53B EV / Sales 2024
1.59x
EV / Sales 2025 * 1.39x
Free-Float
80.61%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+8.59%
1 week-8.92%
Current month-10.37%
1 month-14.44%
3 months+69.57%
6 months+11.15%
Current year-3.20%
More quotes
1 week
15.38
Extreme 15.38
18.68
1 month
15.38
Extreme 15.38
21.25
Current year
15.38
Extreme 15.38
21.25
1 year
9.18
Extreme 9.18
24.00
3 years
8.44
Extreme 8.44
34.30
5 years
8.44
Extreme 8.44
85.70
10 years
8.44
Extreme 8.44
144.75
More quotes
Director TitleAgeSince
Chief Executive Officer 53 2013-02-04
Director of Finance/CFO 58 2022-08-31
Chief Tech/Sci/R&D Officer - 2022-10-25
Manager TitleAgeSince
Director/Board Member 63 2001-12-31
Director/Board Member 69 2019-04-10
Chairman 66 2020-04-15
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+8.59%-8.92%+16.99%-23.56% 54.67M
-0.66%-2.93%-11.66%-22.72% 62.13B
-0.55%+2.08%+66.26%+73.28% 7.42B
-1.92%-2.41%-25.68%-28.46% 7.11B
+0.80%-1.26%+44.47%+57.93% 6.83B
-1.26%-8.59%+98.11%+139.99% 6.51B
+0.06%-12.06%+22.01%-11.53% 2.95B
-1.06%+1.85%+41.91%+29.63% 2.16B
+0.79%-1.79%+30.95%+27.48% 2.14B
+0.89%+1.56%-36.51%+48.31% 1.79B
Average +0.57%-3.19%+24.68%+29.04% 9.91B
Weighted average by Cap. -0.60%-2.82%+6.90%+4.14%
See all sector performances

Financials

2024 2025 *
Net sales 587M 54.9M 52.27M 49.29M 43.54M 77.78M 4.76B 86.31M 217M 1.99B 206M 202M 8.35B 608M 56.87M 54.14M 51.06M 45.1M 80.57M 4.93B 89.41M 225M 2.06B 213M 209M 8.65B
Net income -159M -14.84M -14.12M -13.32M -11.77M -21.02M -1.29B -23.32M -58.76M -537M -55.62M -54.49M -2.26B -57.41M -5.37M -5.11M -4.82M -4.26M -7.61M -465M -8.44M -21.27M -195M -20.13M -19.72M -817M
Net Debt 367M 34.31M 32.66M 30.81M 27.21M 48.61M 2.97B 53.94M 136M 1.24B 129M 126M 5.22B 262M 24.49M 23.31M 21.99M 19.42M 34.69M 2.12B 38.5M 96.99M 887M 91.8M 89.95M 3.72B
More financial data * Estimated data
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
110
More about the company
Date Price Change Volume
25-02-14 16.94 kr +8.59% 26,141
25-02-13 15.60 kr -2.62% 19,504
25-02-12 16.02 kr -4.76% 25,374
25-02-11 16.82 kr -5.29% 27,971
25-02-10 17.76 kr -4.52% 17,354

Delayed Quote Nasdaq Stockholm, February 14, 2025 at 12:00 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings

Quarterly revenue - Rate of surprise